Company intelligence / Profile preview

APT Pharmaceuticals

Burlingame, California, United States

Ownership: Private
Development stage: Phase 3

Overview

APT Pharmaceuticals developed inhaled cyclosporine for inflammatory diseases and transplantation. Its lead program, Pulminiq, advanced to a pivotal Phase III trial for prevention of lung transplant rejection. The company also pursued a novel cardioprotectant and other specialty drug projects targeting significant unmet medical needs. No recent clinical results are publicly available; most information dates from the late 2000s.

Therapeutic areas: ImmunologyCardiovascular
Modalities: Inhaled therapeuticsSmall molecules (e.g., cyclosporine)
Industry: Biotech

Drug pipeline

1 asset

Pulminiq

Phase 3

Indications: Lung transplant rejection

Partnerships

No major pharmaceutical partnerships disclosed; primary relationships are with venture capital investors.

Beyond the preview

Go deeper on APT Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APT Pharmaceuticals.

Explore the full profile